Inicio>>Signaling Pathways>> Apoptosis>>ONO-7475

ONO-7475 (Synonyms: ONO-7475)

Catalog No.GC18416

ONO-7475 es un inhibidor de Axl/Mer potente, selectivo y oralmente activo con valores IC50 de 0,7 nM y 1,0 nM, respectivamente. ONO-7475 sensibiliza las células de NSCLC mutantes de EGFR que sobreexpresan AXL a los EGFR-TKI, suprime la apariciÓn y el mantenimiento de células tolerantes. ONO-7475 combinado con Osimertinib ofrece una gran promesa para el estudio del cÁncer de pulmÓn de células no pequeÑas (CPCNP) con mutaciÓn de EGFR.

Products are for research use only. Not for human use. We do not sell to patients.

ONO-7475 Chemical Structure

Cas No.: 1646839-59-9

Tamaño Precio Disponibilidad Cantidad
10mM 1 mL in DMSO
172,00 $
Disponible
5mg
140,00 $
Disponible
10mg
216,00 $
Disponible
50mg
540,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ONO-7475 is a potent and orally active Axl/Mer inhibitor. ONO-7475 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis

Reference:
[1]: Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Lung Cancer. Clin Cancer Res. 2020 Jan 17. doi: 10.1158/1078-0432.CCR-19-2321. Epub ahead of print. PMID: 31953310.
[2]: Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica. 2017 Dec;102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14. PMID: 28912176; PMCID: PMC5709104.

Reseñas

Review for ONO-7475

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ONO-7475

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.